相似文献
1
Insights into Molecular and Cellular Mechanisms of NeuroCOVID.
Cells. 2024 Oct 29;13(21):1790. doi: 10.3390/cells13211790.
2
Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study.
PLoS Med. 2025 Jan 23;22(1):e1004511. doi: 10.1371/journal.pmed.1004511. eCollection 2025 Jan.
3
Intranasal Route: A Nasocerebral Approach against SARS-CoV-2 in NeuroCOVID.
ACS Chem Neurosci. 2023 Oct 4;14(19):3560-3563. doi: 10.1021/acschemneuro.3c00488. Epub 2023 Sep 12.
4
Post-Acute Sequelae and Mitochondrial Aberration in SARS-CoV-2 Infection.
Int J Mol Sci. 2024 Aug 21;25(16):9050. doi: 10.3390/ijms25169050.
5
15-month post-COVID syndrome in outpatients: Attributes, risk factors, outcomes, and vaccination status - longitudinal, observational, case-control study.
Front Immunol. 2023 Sep 12;14:1226622. doi: 10.3389/fimmu.2023.1226622. eCollection 2023.
6
Post-coronavirus disease 2019-associated symptoms among children and adolescents in the SARS-CoV-2 Omicron era.
Eur J Pediatr. 2024 Dec 21;184(1):96. doi: 10.1007/s00431-024-05919-3.
7
A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.
BMC Infect Dis. 2021 Jul 13;21(1):677. doi: 10.1186/s12879-021-06359-2.
8
The Potential Role of Viral Persistence in the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC).
Pathogens. 2024 May 8;13(5):388. doi: 10.3390/pathogens13050388.
9
Symptom evolution in individuals with ongoing symptomatic COVID-19 and post-COVID-19 syndrome after SARS-CoV-2 vaccination versus influenza vaccination.
J Infect. 2025 Feb;90(2):106406. doi: 10.1016/j.jinf.2024.106406. Epub 2025 Jan 10.
10
Pathological disease in the lung periphery after acute COVID-19.
Lancet Respir Med. 2021 Oct;9(10):1089-1090. doi: 10.1016/S2213-2600(21)00378-7. Epub 2021 Sep 7.
引用本文的文献
1
Insight into NeuroCOVID: neurofilament light chain (NfL) as a biomarker in post-COVID-19 patients with olfactory dysfunctions.
J Neurol. 2025 Jul 1;272(7):484. doi: 10.1007/s00415-025-13222-w.
本文引用的文献
1
Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19.
Nat Commun. 2024 Oct 17;15(1):8941. doi: 10.1038/s41467-024-53356-5.
2
Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations.
Brain. 2024 Dec 3;147(12):4121-4130. doi: 10.1093/brain/awae215.
3
How long COVID could lift the fog on neurocognitive disorders.
Nature. 2024 Oct;634(8032):S11. doi: 10.1038/d41586-024-03047-4.
4
Controversies in COVID-19: Diagnostic Evaluation and Management in Neuro-COVID.
Adv Exp Med Biol. 2024;1457:185-197. doi: 10.1007/978-3-031-61939-7_10.
5
Long COVID science, research and policy.
Nat Med. 2024 Aug;30(8):2148-2164. doi: 10.1038/s41591-024-03173-6. Epub 2024 Aug 9.
6
The National Institutes of Health COVID-19 Neuro Databank/Biobank: Creation and Evolution.
Neuroepidemiology. 2024 Jun 26:1-13. doi: 10.1159/000539830.
7
The European Academy of Neurology NeuroCOVID-19 Task Force: A lesson for the future.
Eur J Neurol. 2025 Jan;32(1):e16321. doi: 10.1111/ene.16321. Epub 2024 Apr 26.
8
Intranasal Route: A Nasocerebral Approach against SARS-CoV-2 in NeuroCOVID.
ACS Chem Neurosci. 2023 Oct 4;14(19):3560-3563. doi: 10.1021/acschemneuro.3c00488. Epub 2023 Sep 12.
9
Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics.
Cells. 2023 Mar 6;12(5):816. doi: 10.3390/cells12050816.
10
COVID-19 Affects Serum Brain-Derived Neurotrophic Factor and Neurofilament Light Chain in Aged Men: Implications for Morbidity and Mortality.
Cells. 2023 Feb 17;12(4):655. doi: 10.3390/cells12040655.
Zotero 插件